Epoch Investment Partners Inc. Lowers Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• Epoch Investment Partners Inc. reduced its stake in Medpace Holdings, Inc. by 8.7%, now owning approximately 1.39% of the company valued at $121.8 million after selling 38,304 shares.
• Medpace's CFO and CEO have both sold significant amounts of stock recently, with the CFO selling 12,000 shares and the CEO selling 48,487 shares, indicating a decrease in insider ownership.
• Brokerage firms have mixed ratings on Medpace, with price targets ranging from $305 to $430, while analysts forecast earnings per share of 12.29 for the current fiscal year.

Epoch Investment Partners Inc. trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 8.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 399,796 shares of the company's stock after selling 38,304 shares during the quarter. Epoch Investment Partners Inc. owned 1.39% of Medpace worth $121,814,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brooklyn Investment Group lifted its position in shares of Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after purchasing an additional 71 shares during the last quarter. Whittier Trust Co. lifted its position in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares during the last quarter. Colonial Trust Co SC increased its stake in shares of Medpace by 150.0% during the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after buying an additional 105 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Medpace during the first quarter valued at $60,000. Finally, Assetmark Inc. increased its stake in shares of Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after buying an additional 43 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Price Performance

Medpace stock traded down $0.54 during midday trading on Thursday, reaching $472.94. The company's stock had a trading volume of 202,838 shares, compared to its average volume of 356,826. The stock's 50-day simple moving average is $392.42 and its 200-day simple moving average is $338.34. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $501.30. The stock has a market capitalization of $13.28 billion, a P/E ratio of 35.16, a PEG ratio of 2.98 and a beta of 1.42.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm's revenue was up 14.2% compared to the same quarter last year. During the same period last year, the business posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

MEDP has been the topic of several research reports. TD Cowen restated a "sell" rating and set a $366.00 price target (up previously from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Barclays raised their price target on Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Mizuho raised their price objective on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Deutsche Bank Aktiengesellschaft raised their price objective on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Finally, William Blair reaffirmed a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Reduce" and an average target price of $406.60.

Insiders Place Their Bets

In other news, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. This represents a 22.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $450.14, for a total value of $3,376,050.00. Following the completion of the transaction, the vice president directly owned 57,500 shares in the company, valued at $25,883,050. This represents a 11.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 115,070 shares of company stock valued at $52,085,751. Insiders own 20.30% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.